Search Result

Results for "

α-amylase inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amylases (72) Amyloid-β (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (3) Bacterial (1) Bcl-2 Family (1) Caspase (1) Cholinesterase (ChE) (2) COX (2) Dipeptidyl Peptidase (3) DNA/RNA Synthesis (1) Drug Intermediate (1) Endogenous Metabolite (2) Fatty Acid Synthase (FASN) (2) Fungal (2) GLUT (3) Glycosidase (50) HDAC (1) Lipase (1) MDM-2/p53 (1) Monoamine Oxidase (1) NF-κB (6) NOD-like Receptor (NLR) (2) P-glycoprotein (1) P2Y Receptor (1) p38 MAPK (1) PARP (1) Phosphatase (2) PPAR (2) Pregnane X Receptor (PXR) (1) Pyroptosis (2) Reactive Oxygen Species (ROS) (1) Reference Standards (4) SARS-CoV (1) Tyrosinase (1) β-glucuronidase (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (2) Endocrinology (4) Infection (2) Inflammation/Immunology (14) Metabolic Disease (75) Neurological Disease (4)

By Targets:

Amylases (72)

Amyloid-β (1)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (3)

Bacterial (1)

Bcl-2 Family (1)

Caspase (1)

Cholinesterase (ChE) (2)

COX (2)

Dipeptidyl Peptidase (3)

DNA/RNA Synthesis (1)

Drug Intermediate (1)

Endogenous Metabolite (2)

Fatty Acid Synthase (FASN) (2)

Fungal (2)

GLUT (3)

Glycosidase (50)

HDAC (1)

Lipase (1)

MDM-2/p53 (1)

Monoamine Oxidase (1)

NF-κB (6)

NOD-like Receptor (NLR) (2)

P-glycoprotein (1)

P2Y Receptor (1)

p38 MAPK (1)

PARP (1)

Phosphatase (2)

PPAR (2)

Pregnane X Receptor (PXR) (1)

Pyroptosis (2)

Reactive Oxygen Species (ROS) (1)

Reference Standards (4)

SARS-CoV (1)

Tyrosinase (1)

β-glucuronidase (1)

By Research Areas:

Cancer (12)

Cardiovascular Disease (2)

Endocrinology (4)

Infection (2)

Inflammation/Immunology (14)

Metabolic Disease (75)

Neurological Disease (4)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132179

Fucoidan Maximum Cited Publications 6 Publications Verification	Glycosidase	Cardiovascular Disease Metabolic Disease Cancer
Fucoidan, a biologically active polysaccharide, is an efficient inhibitor of α-amylase and α-glucosidase. Anticoagulant, antitumor, antioxidant and antisteatotic activities .

HY-N1425

Tiliroside 3 Publications Verification	Others	Metabolic Disease
Tiliroside, a glycosidic flavonoid, possesses anti-diabetic activities. Tiliroside is a noncompetitive inhibitor of *α-amylase* with a K_i value of 84.2 μM. Tiliroside inhibits carbohydrate digestion and glucose absorption in the gastrointestinal tract .

HY-N0668

Rubusoside 2 Publications Verification	GLUT Amylases NF-κB	Metabolic Disease Inflammation/Immunology Cancer
Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) .

HY-126052

Gnetol	COX Tyrosinase HDAC	Metabolic Disease Cancer
Gnetol is a phenolic compound isolated from the root of Gnetum montanum . Gnetol potently inhibits COX-1 (IC₅₀ of 0.78 μM) and HDAC. Gnetol is a potent tyrosinase inhibitor with an IC₅₀ of 4.5 μM for murine tyrosinase and suppresses melanin biosynthesis. Gnetol has antioxidant, antiproliferative, anticancer and hepatoprotective activity. Gnetol also possesses concentration-dependent α-Amylase, α-glucosidase, and adipogenesis activities .

HY-N2376

Chrysin-7-O-glucuronide 1 Publications Verification	Glycosidase Amylases NF-κB	Metabolic Disease Inflammation/Immunology
Chrysin-7-O-glucuronide is a flavonoid found in Scutellaria baicalensis. Chrysin-7-O-glucuronide inhibits α-glucosidase and *α-amylase* with IC₅₀ values of 612.13 and 980.73 μg/mL. Chrysin-7-O-glucuronide suppresses NF-κB signaling activity. Chrysin-7-O-glucuronide scavenges free radicals, acts as a tight junction protector, and mitigates intestinal mucosal barrier injury. Chrysin-7-O-glucuronide can be used for the research of type 2 diabetes and severe acute pancreatitis-induced intestinal mucosal barrier injury .

HY-N6675

Gardenia yellow	Amylases Glycosidase	Inflammation/Immunology
Gardenia yellow is a competitive inhibitor of *α-Amylase* (HY-B2193) and α-glucosidase. Gardenia yellow can bind to the catalytic sites of *α-Amylase* and α-glucosidase, inhibit starch digestion, and significantly increase the contents of resistant starch and slowly digestible starch in starch-based systems. Gardenia yellow reduces the glycemic index and hydrolysis index. Gardenia yellow can be used in diabetes-related research .

HY-Y0598

trans-Chalcone 2 Publications Verification Benzylideneacetophenone	Fatty Acid Synthase (FASN) Apoptosis Fungal	Inflammation/Immunology Cancer
trans-Chalcone, isolated from Aronia melanocarpa skin, is a biphenolic core structure of flavonoids precursor. trans-Chalcone is a potent fatty acid synthase (FAS) and *α-amylase* inhibitor. trans-Chalcone causes cellcycle arrest and induces apoptosis in the breastcancer cell line MCF-7. trans-Chalcone has antifungal and anticancer activity .

HY-N8599

Cichoriin 2 Publications Verification	Amylases Glycosidase Lipase Dipeptidyl Peptidase p38 MAPK PPAR P2Y Receptor NOD-like Receptor (NLR) SARS-CoV Pyroptosis GLUT Angiotensin-converting Enzyme (ACE) NF-κB	Infection Metabolic Disease Inflammation/Immunology
Cichoriin is an orally active coumarin glycoside with broad biological activities. Cichoriin exhibits inhibitory activities against *α-amylase, α-glucosidase, pancreatic lipase* and DPP-IV, with IC₅₀ values of 5.76, 2.94, 16.83 and 9.16 μg/mL, respectively. Cichoriin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway. Cichoriin upregulates PPAR-γ in adipose tissue and alleviates obesity and associated cardiorenal injury in rats. Cichoriin blocks monosodium urate crystal-induced activation of the NLRP3 inflammasome and cell pyroptosis by inhibiting P2Y₁₄R (IC₅₀ = 8.47 nM). In silico virtual screening reveals that Cichoriin has a strong binding affinity for SARS-CoV-2 .

HY-W068682

1-Hydroxyphenazine Hemipyocyanine; 1-Phenazinol; Hemi-pyocyanin	Amylases Bacterial	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
1-Hydroxyphenazine (Hemipyocyanine; 1-Phenazinol; Hemi-pyocyanin) is an inhibitor for *α-Amylase* with an IC₅₀ of 3.1 μg/mL . 1-Hydroxyphenazine exhibits anticancer and anti-inflammatory activity against cells A549, 1321N1 and RAW264.7, antifungal and antibacterial activity against strains Candida albicans, Aspergillus fumigatus, Escherichia coli and Xanthomonas campestris .

HY-135530

Chinese gallotannin	Amylases	Metabolic Disease
Chinese gallotannin is a non-specific promiscuous *α-amylase* inhibitor with a K_i of 0.82 μg/mL for human salivary α-amylase. Chinese gallotannin can be used for the research of diabetes .

HY-W005598

2-Hydroxyquinoline	Glycosidase Amylases	Metabolic Disease
2-Hydroxyquinoline is an inhibitor of α-glucosidase and *α-amylase* with IC₅₀ values of 64.4 µg/mL and 130.5 µg/mL, respectively. 2-Hydroxyquinoline can be used in the study of diabetes .

HY-N4309

Lotusine	Amylases Glycosidase	Neurological Disease Metabolic Disease Cancer
Lotusine is an orally active signaling pathway modulator and enzyme inhibitor, with an IC₅₀ of 30.60 μg/mL against *α-amylase* and an IC₅₀ of 36.15 μg/mL against α-glucosidase. Lotusine inhibits the EGFR-Akt-ERK signaling pathway by reducing the levels of phosphorylated EGFR, Akt and ERK. Lotusine induces apoptosis, triggers G₀/G₁ cell cycle arrest and inhibits cancer cell proliferation. Lotusine reduces lipid peroxidation and increases the activities of SOD, CAT and GPx. Lotusine is applicable to researches related to non-small cell lung cancer, type 2 diabetes and autism spectrum disorder .

HY-200541

Dihydro-α-ionone	Others	Metabolic Disease
Dihydro-α-ionone is a volatile compound found in the essential oil of Persicaria hydropiper L. leaves. The essential oil can inhibit α-glucosidase and α-amylase activities .

HY-146752

α-Amylase-IN-1	Amylases	Others
α-Amylase-IN-1 is a potent *α-amylase* inhibitor with an IC_{50 of 4.46 μM .}

HY-N12999

Stigmast-5-en-3-ol	Apoptosis Bcl-2 Family Caspase MDM-2/p53 PARP Amylases	Metabolic Disease Endocrinology Cancer
Stigmast-5-en-3-ol induces cancer cell apoptosis and inhibits proliferation by increasing the production of Bax, Caspase-9, p53, and PARP cleavage and reducing Bcl-xl expression. Stigmast-5-en-3-ol exhibits potent inhibitory activity against glucoamylase and *α-amylase* and possesses high antioxidant activity. Stigmast-5-en-3-ol can be used in the research of diseases such as leukemia, breast cancer, type 2 diabetes, and obesity .

HY-N17254

Onjisaponin R	Amylases	Metabolic Disease
Onjisaponin R is an *α-amylase* inhibitor. Onjisaponin R can be used in diabetes research .

HY-N9454

Garcinoic acid	Pregnane X Receptor (PXR) COX NF-κB Amylases β-glucuronidase DNA/RNA Synthesis Amyloid-β NOD-like Receptor (NLR) Pyroptosis	Cancer
Garcinoic acid is an orally active anti-inflammatory agent that crosses the blood-brain barrier. Garcinoic acid also enhances efferocytosis and enzyme/receptor regulation, and selectively inhibits human COX-2, porcine *α-amylase, Saccharomyces cerevisiae α-glucosidase* and human DNA polymerase β (IC₅₀=11 μM), as well as activates human PXR. Garcinoic acid enhances macrophage efferocytosis via receptors such as MerTK and LRP-1, and promotes the production of pro-resolving lipid mediators. Garcinoic acid inhibits NF-κB activation and pro-inflammatory cytokine secretion, interferes with Aβ aggregation, downregulates NLRP3 inflammasome activity, and binds to targets including CD44 and EGFR to inhibit leukemia cell proliferation. The pharmacological activities of Garcinoic acid, such as antioxidant, anti-inflammatory and lipid metabolism-regulating effects, are widely used in studies related to various diseases including atherosclerosis, Alzheimer's disease, type 2 diabetes, inflammatory bowel disease and viral pneumonia .

HY-W008168

Quinoline-2-carboxaldehyde 2-Quinolinecarboxaldehyde	Drug Intermediate	Others
Quinoline-2-carboxaldehyde (2-Quinolinecarboxaldehyde) is a quinoline derivative that serves as a synthetic precursor for Schiff base copper complexes. Quinoline-2-carboxaldehyde is applicable to research related to the synthetic design of biomaterials or organic compounds, such as fluorescent sensors .

HY-178363

α-Amylase-IN-13	Amylases	Metabolic Disease Endocrinology
α-Amylase-IN-13 is an orally active, selective, brain-penetrant *α-amylase* inhibitor (IC₅₀ = 0.71 μM). α-Amylase-IN-13 inhibits α-amylase through a mixed type of inhibition mechanism. α-Amylase-IN-13 leads to a significant reduction in blood glucose level in diabetic rats. α-Amylase-IN-13 causes significant histopathological improvements in the kidney, liver, and pancreas. α-Amylase-IN-13 can be used for the study of diabetic complications .

HY-133718

Acarviosin (S)-Acarviosin	Amylases	Others
Acarviosin, a pseudodisaccharide moiety, is a part of the potent inhibitor of α-amylase .

HY-179141

α-Amylase/α-Glucosidase-IN-23	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-23 (Compound 5e) is a *α-Amylase/α-Glucosidase* inhibitor with IC₅₀ values of 73.68 nM for α-glucosidase and 146.18 nM for α-amylase. α-Amylase/α-Glucosidase-IN-23 can be used in the research of hypoglycemia .

HY-149008

α-Amylase-IN-3	Amylases Cholinesterase (ChE)	Inflammation/Immunology
α-Amylase-IN-3 (Compound 4) is the inhibitor for *α-Amylase, AChE* and AChE with IC₅₀s of 18.04 μM, 21.04 μM and 22.2 μM, respectively. α-Amylase-IN-3 exhibits antioxidant activity. α-Amylase-IN-3 can be used in research of diabetes and oxidative stress associated disease .

HY-N10413

Diphlorethohydroxycarmalol	Glycosidase	Metabolic Disease
Diphlorethohydroxycarmalol, a kind of phlorotannin, is an orally active α-glucosidase and *α-amylase* inhibitor with IC₅₀s of 0.16 mM and 0.53 mM, respectively. Diphlorethohydroxycarmalol has anti-diabetic activities .

HY-179511

α-Glucosidase-IN-104	Glycosidase	Metabolic Disease
α-Glucosidase-IN-104 (Compound 9s) is an efficient inhibitor of α-glucosidase with an IC₅₀ of 24.32 μM. α-Glucosidase-IN-104 has a weak inhibitory effect on α-amylase and avoids gastrointestinal side effects. α-Glucosidase-IN-104 can be used for research on type 2 diabetes .

HY-178935

α-Amylase-IN-14	Amylases Reactive Oxygen Species (ROS)	Metabolic Disease Inflammation/Immunology
α-Amylase-IN-14, a derivative of Nicotinic (HY-B0143), is an *α-amylase* inhibitor and has good interactions with α-amylase protein (-5.55 kcal/mol). α-Amylase-IN-14 is a dual anti-inflammatory and anti-hyperglycemic agent. α-Amylase-IN-14 exhibits good results against DPPH and ABTS radicals. α-Amylase-IN-14 can be used for the study of diabetes .

HY-175605

α-Amylase/α-Glucosidase-IN-21	Glycosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-21 (Compound 4) is a dual-functional inhibitor of α-Glucosidase and *α-Amylase* with IC₅₀s of 0.27 and 0.19 µg/mL for α-Glucosidase and α-Amylase, respectively. α-Amylase/α-Glucosidase-IN-21 has an antidiabetic activity.α-Amylase/α-Glucosidase-IN-21 can be used for diabetes mellitus research .

HY-161944

α-Amylase-IN-8	Amylases	Metabolic Disease
α-Amylase-IN-8 (compound 44) is an *α-amylase* inhibitor (IC₅₀=58.1 μM). α-Amylase-IN-8 can be used in the research of type 2 diabetes .

HY-155241

α-Amylase/α-Glucosidase-IN-4	Glycosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-4 (compound 5) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC₅₀s of 0.15 μM and 1.10 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .

HY-W112651

2,4,6-Triphenylaniline	Glycosidase Amylases	Metabolic Disease
2,4,6-Triphenylaniline has anti-diabetic activity and can be encapsulated in nano-emulsions (NE) to enhance stability and permeability. The NE loaded with 2,4,6-Triphenylaniline inhibits α-glucosidase and *α-amylase* .

HY-169737

Inulobiose	Glycosidase Amylases	Metabolic Disease
Inulobiose is a difructan disaccharide that can be isolated from Pistacia vera L.. Inulobiose inhibits α-glycosidase and *α-amylase* activities with IC₅₀s of 1.87 and 40.72 mg/mL, respectively. Inulobiose can be used for the research of diabetes and glomerular filtration rate testing .

HY-N0668R

Rubusoside (Standard)	GLUT Amylases NF-κB Reference Standards	Metabolic Disease Inflammation/Immunology Cancer
Rubusoside (Standard) is the analytical standard of Rubusoside. This product is intended for research and analytical applications. Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits *NF-κB and α-amylase* (α-amylase) .**

HY-149313

α‑Amylase-IN-1	Amylases	Metabolic Disease
α Amylase-IN-1 (Compound 11) is an *α-Amylase* inhibitor with an IC₅₀ value of 0.5509 μM. α Amylase-IN-1 has antioxidant activity with an IC₅₀ value of 53.49 μM for scavenging DPPH free radicals. IC₅₀ can be used in the study of diabetes and oxidative stress-related diseases.

HY-174319

α-Amylase/α-Glucosidase-IN-20	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-20 (Compound 6b) is a dual inhibitor of *α-Amylase* and α-Glucosidase with IC₅₀s of 414.57 and 924.15 μM for α-Amylase and α-Glucosidase, respectively. α-Amylase/α-Glucosidase-IN-20 shows a potent anti-diabetic activity, promising for diabetes research .

HY-162673

α-Amylase/α-Glucosidase-IN-16	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-16 (compound 15) is a potent dual inhibitor of *α-amylase* and α-Glucosidase with IC₅₀ values of 0.8 and 1.2 μM, respectively. α-Amylase/α-Glucosidase-IN-16 can be used in the study of diabetes mellitus (DM) .

HY-N12263

3,5,6,7,8,4'-Hexamethoxyflavone	Amylases	Metabolic Disease
3,5,6,7,8,4'-Hexamethoxyflavone is a inhibitor of *α-Amylase* with the inhibitory activity of 28.3% at 500 μM .

HY-W207699

MAO-B-IN-46	Monoamine Oxidase Amylases	Neurological Disease Metabolic Disease Inflammation/Immunology
MAO-B-IN-46 (Compound 16) is a selective hMAO-B inhibitor (IC₅₀: 26.8 nM), with weak activity against hMAO-A (IC₅₀: 7.2054 μM). MAO-B-IN-46 (Compound 8) also acts as an *α-amylase* inhibitor (IC₅₀: 19.46 μM). MAO-B-IN-46 exhibits certain neuroprotective effects and shows no significant toxicity to human gingival fibroblasts and SH-SY5Y cells. Additionally, MAO-B-IN-46 can scavenge DPPH and ABTS free radicals, with IC₅₀ values of 17.86 μM and 17.71 μM, respectively. MAO-B-IN-46 can be used in the research of neurodegenerative diseases such as Parkinson's disease, diabetes, and diseases related to oxidative stress resistance .

HY-N11844

Quercetin 3-(6″-caffeoylsophoroside)	Amylases	Metabolic Disease
Quercetin 3-(6″-caffeoylsophoroside) is an orally active *α-amylase* inhibitor, with an IC₅₀ of 73.66 μg/mL. Quercetin 3-(6″-caffeoylsophoroside) presents in thehydro-methanolic extract of Cardamine hirsuta Linn. Quercetin 3-(6″-caffeoylsophoroside) shows the antidiabetic activities by oxidative stress reduction and α-amylase inhibition. Quercetin 3-(6″-caffeoylsophoroside) can be used for diabetes mellitus research .

HY-N11728

2,7"-Phloroglucinol-6,6'-bieckol	Amylases Glycosidase	Metabolic Disease
2,7"-Phloroglucinol-6,6'-bieckol is an orally active dual *α-amylase/α-glucosidase* inhibitor with IC₅₀ values of 6.94 μM and 23.35 μM respectively. 2,7"-Phloroglucinol-6, 6'-bieckol alleviates postprandial hyperglycemia in diabetic mice. 2,7"-Phloroglucinol-6,6'-bieckol can be used in diabetes research .

HY-157537

α-Amylase-IN-5	Amylases	Metabolic Disease
α-Amylase-IN-5 (compound 3a) is a *α-amylase* inhibitor, with an IC₅₀ of 18.8 mM .

HY-146225

α-Amylase/α-Glucosidase-IN-2	Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-2 (compound 5) is a potent *α-amylase* and α-glucosidase dual inhibitor with IC₅₀ values of 13.02, 13.09 µM for α-amylase and α-glucosidase, respectively. α-Amylase/α-Glucosidase-IN-2 has the potential for the research of diabetic complications .

HY-161782

α-Amylase-IN-7	Amylases	Metabolic Disease
α-Amylase-IN-7 (Compound 6e) is an inhibitor for *α-Amylase* with an IC₅₀ of 40 μM. α-Amylase-IN-7 exhibits potential as an antidiabetic agent .

HY-170548

α-Amylase-IN-10	Amylases	Metabolic Disease
α-Amylase-IN-10 (Compound 15n) is an inhibitor for *α-Amylase* with an IC₅₀ of 5.00 µM. α-Amylase-IN-10 can be used for research of type 2 diabetes mellitus .

HY-168598

α-Amylase-IN-9	Amylases	Metabolic Disease
α-Amylase-IN-9 (Compound 1i) is an inhibitor of *α-Amylase* with an IC₅₀ value of 14.64 μM, which can be used in diabetes research .

HY-172622

α-Amylase/α-Glucosidase-IN-19	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-19 (compound 10) is a dual inhibitor of α-amylase /α-glucosidase (IC₅₀= 170.7 μM and 60.37 μM, respectively) .

HY-168961

α-Amylase/α-Glucosidase-IN-18	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-18 (Compound 9g) is the inhibitor for *α-Amylase* and α-Glucosidase with IC₅₀ of 49.17 nM and 10.71 nM. α-Amylase/α-Glucosidase-IN-18 can be used in research of type 2 diabetes mellitus .

HY-162634

α-Amylase/α-Glucosidase-IN-15	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-15 (compound 6C) is an oral bioactive inhibitor of α-Glucosidase and *α-amylase, with the IC₅₀*s of 21 μM and 61 μM, respectively .

HY-147711

α-Amylase/α-Glucosidase-IN-1	Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-1 (compound 33) is a potent *α-amylase/α-glucosidase* inhibitor with IC₅₀s of 2.01, 2.09 µM for α-amylase and α-glucosidase, respectively. Kinetic studies predict that α-Amylase/α-Glucosidase-IN-1 has the potential of anti hyperglycemia .

HY-161355

α-Amylase/α-Glucosidase-IN-9	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-9 (compound 5h) is a dual inhibitor for both *α-amylase* (IC₅₀ = 16.4 μM) and α-glucosidase (IC₅₀ = 31.6 μM) enzymes .

HY-162635

α-Amylase/α-Glucosidase-IN-14	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-14 (compound 6E) is an oral bioactive inhibitor of *α-amylase* and α-glucosidase, with the IC₅₀s of 45.53 μM and 27.73 μM, respectively .

HY-149557

α-Amylase/α-Glucosidase-IN-5	Glycosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-5 (compound 4l) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC₅₀s of 5.96 μM and 1.62 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .

Cat. No.	Product Name	Type

HY-W005598

2-Hydroxyquinoline	Biochemical Assay Reagents
2-Hydroxyquinoline is an inhibitor of α-glucosidase and *α-amylase* with IC₅₀ values of 64.4 µg/mL and 130.5 µg/mL, respectively. 2-Hydroxyquinoline can be used in the study of diabetes .

HY-W008168

Quinoline-2-carboxaldehyde 2-Quinolinecarboxaldehyde	Biochemical Assay Reagents
Quinoline-2-carboxaldehyde (2-Quinolinecarboxaldehyde) is a quinoline derivative that serves as a synthetic precursor for Schiff base copper complexes. Quinoline-2-carboxaldehyde is applicable to research related to the synthetic design of biomaterials or organic compounds, such as fluorescent sensors .

Cat. No.	Product Name	Target	Research Area

HY-P2055

A-57696	Endogenous Metabolite	Endocrinology
A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks